Medexus Pharmaceuticals Inc.

TSX:MDP Rapporto sulle azioni

Cap. di mercato: CA$53.0m

Medexus Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Medexus Pharmaceuticals Il CEO è Ken d'Entremont, nominato in Dec2018, e ha un mandato di 5.92 anni. la retribuzione annua totale è $ 1.11M, composta da 46.8% di stipendio e 53.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.99% delle azioni della società, per un valore di CA$ 3.18M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.5 anni e 6.1 anni.

Informazioni chiave

Ken d'Entremont

Amministratore delegato

US$1.1m

Compenso totale

Percentuale dello stipendio del CEO46.8%
Mandato del CEO5.9yrs
Proprietà del CEO6.0%
Durata media del management4.5yrs
Durata media del Consiglio di amministrazione6.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Nov 05
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth

Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth

The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 11
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Jan 19
Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 22
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Dec 16
Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ken d'Entremont rispetto agli utili di Medexus Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

US$2m

Jun 30 2024n/an/a

US$1m

Mar 31 2024US$1mUS$517k

-US$214k

Dec 31 2023n/an/a

US$6m

Sep 30 2023n/an/a

US$5m

Jun 30 2023n/an/a

US$3m

Mar 31 2023US$882kUS$400k

US$1m

Dec 31 2022n/an/a

-US$11m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

US$2m

Mar 31 2022US$592kUS$400k

-US$3m

Dec 31 2021n/an/a

-US$8m

Sep 30 2021n/an/a

-US$20m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021US$688kUS$328k

-US$28m

Dec 31 2020n/an/a

-US$19m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020US$385kUS$300k

-US$5m

Dec 31 2019n/an/a

-US$4m

Sep 30 2019n/an/a

-US$3m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019US$2mUS$144k

-US$5m

Compensazione vs Mercato: La retribuzione totale di Ken ($USD 1.11M ) è superiore alla media delle aziende di dimensioni simili nel mercato Canadian ($USD 169.37K ).

Compensazione vs guadagni: La retribuzione di Ken è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Ken d'Entremont

5.9yrs

Mandato

US$1,106,271

Compensazione

Mr. Kenneth d'Entremont, also known as Ken, has been Chief Executive Officer at Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) since December 17,2018 and served as its Chief Operating Officer sinc...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Kenneth d'Entremont
CEO & Director5.9yrsUS$1.11m5.99%
CA$ 3.2m
Richard Labelle
Chief Operating Officerno dataUS$374.12k0.093%
CA$ 49.3k
Ian Wildgoose Brown
General Counsel & Corporate Secretary3yrsUS$446.08k0.084%
CA$ 44.4k
Brendon Buschman
Chief Financial Officerless than a yearNessun datoNessun dato
Tina Byers
Executive of Investor Relationsno dataNessun datoNessun dato
Bill Poncy
Senior Vice President of Commercial Operations - United States6.1yrsUS$439.69kNessun dato
Brian Peters
Vice President of Sales & Marketing - United Statesno dataUS$281.91kNessun dato

4.5yrs

Durata media

Gestione esperta: Il team dirigenziale di MDP è considerato esperto (durata media dell'incarico 4.5 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Kenneth d'Entremont
CEO & Director6.1yrsUS$1.11m5.99%
CA$ 3.2m
Michael Mueller
Independent Chairman10.5yrsUS$94.71k0.39%
CA$ 208.7k
Benoit Gravel
Independent Director7.2yrsUS$83.38k0.26%
CA$ 136.6k
Stephen Nelson
Independent Director6.1yrsUS$73.94k2.25%
CA$ 1.2m
Nancy Phelan
Independent Director1.2yrsUS$39.27k0.045%
CA$ 24.0k
Harmony Garges
Independent Director1.8yrsUS$62.92k0.099%
CA$ 52.5k
Menassie Taddese
Independent Director1.8yrsUS$66.90k0.099%
CA$ 52.5k

6.1yrs

Durata media

55yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MDP sono considerati esperti (durata media dell'incarico 6.1 anni).